FDA D.I.S.C.O. Burst Edition: FDA approvals of Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy for first-line advanced or metastatic esophageal squamous cell carcinoma, a

FDA D.I.S.C.O. Burst Edition: FDA approvals o...

U.S. Food and Drug Administration, Center for Drug Evaluation and ResearchU.S. Food and Drug Administration, Center for Drug Evaluation and Research

Up next

FDA D.I.S.C.O. Burst Edition: FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer

Listen to a soundcast of the March 3, 2023, FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer. 

 . 4min 30sec
FDA D.I.S.C.O. Burst Edition: FDA approval of Jemperli (dostarlimab-gxly) for dMMR endometrial cancer

Listen to a soundcast of the February 9, 2023, FDA approval of Jemperli (dostarlimab-gxly) for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen. 

 . 3min 30sec

Recommended Episodes

179. Back to Basics - Metastatic NSCLC feat. EGFR and ALK Driver Mutations
Oncology for the Inquisitive Mind

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that represent incredible advances over chemotherapy. How incredible? ...  Show more

 . 24min 44sec
Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)
The Fellow on Call: The Heme/Onc Podcast

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ...

  Show more

 . 36min 11sec
DFMO FDA Approval with Dr. Nicole Drezner
This Week in Pediatric Oncology

In this episode Dr. Timothy Cripe and Dr. Brenda Weigel are joined by FDA's Dr. Nicole Drezner, pediatric oncologist and the Deputy Division Director of the Division of Oncology 2 who led the FDA review and publication on the approval of DFMO. Listen in on the discussion surround ...  Show more

 . 35min 23sec
CAR T-Cells and Safety Signals
Intention to Treat

This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701. 

 . 25min 25sec